Title |
Bioequivalence evaluation of epinephrine autoinjectors with attention to rapid delivery
|
---|---|
Published in |
Therapeutics and Clinical Risk Management, April 2013
|
DOI | 10.2147/tcrm.s43774 |
Pubmed ID | |
Authors |
David Alexander Sclar |
Abstract |
Timely and proper injection of epinephrine is critical to prevent serious consequences relating to anaphylaxis. In a recent bioavailability study comparing epinephrine delivery from the Auvi-Q™ and EpiPen(®) epinephrine autoinjectors, the Auvi-Q failed to meet the bioequivalence threshold when using partial area under the curve (AUC) analyses based on zero to Tmax recommended for highly variable drugs such as epinephrine. Peak plasma epinephrine concentrations for the EpiPen occurred 10 minutes (median Tmax) after dosing, while peak concentrations for the Auvi-Q occurred 20 minutes after dosing. Though bioequivalence may be concluded for Cmax, AUCinf, and AUC0-t, for fast-acting therapeutics used to treat life-threatening conditions, such as epinephrine, additional pharmacokinetic parameters such as AUC zero to Tmax may be important to evaluate when assessing bioequivalence. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
Brazil | 1 | 33% |
Australia | 1 | 33% |
Unknown | 1 | 33% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Practitioners (doctors, other healthcare professionals) | 2 | 67% |
Members of the public | 1 | 33% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 16 | 100% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Other | 6 | 38% |
Professor | 2 | 13% |
Researcher | 2 | 13% |
Student > Ph. D. Student | 1 | 6% |
Student > Bachelor | 1 | 6% |
Other | 2 | 13% |
Unknown | 2 | 13% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 7 | 44% |
Pharmacology, Toxicology and Pharmaceutical Science | 3 | 19% |
Nursing and Health Professions | 1 | 6% |
Business, Management and Accounting | 1 | 6% |
Psychology | 1 | 6% |
Other | 1 | 6% |
Unknown | 2 | 13% |